Travere Therapeutics (TVTX) Net Income towards Common Stockholders Growth (5y) (2018 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Travere Therapeutics | 4.34 Bn | 4.26 Bn | 102.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 60.78% |
| Dec 31, 2025 | 17.11% |
| Dec 31, 2024 | 14.87% |
| Sep 30, 2024 | 72.35% |
| Jun 30, 2024 | 54.47% |
| Mar 31, 2024 | 69.80% |
| Dec 31, 2023 | 26.70% |
| Sep 30, 2023 | 44.96% |
| Jun 30, 2023 | 22.25% |
| Mar 31, 2023 | 20.65% |
| Dec 31, 2022 | 25.59% |
| Sep 30, 2022 | 22.95% |
| Jun 30, 2022 | 24.42% |
| Mar 31, 2022 | 20.31% |
| Dec 31, 2021 | -59.49% |
| Sep 30, 2021 | 0.81% |
| Jun 30, 2021 | -23.82% |
| Mar 31, 2021 | -46.73% |
| Dec 31, 2020 | -118.02% |
| Sep 30, 2020 | -17.22% |
| Jun 30, 2020 | -0.42% |
| Mar 31, 2020 | -54.10% |
| Dec 31, 2019 | -0.83% |
| Sep 30, 2019 | -15.21% |
| Jun 30, 2019 | -39.48% |
| Mar 31, 2019 | 11.56% |
| Dec 31, 2018 | 10.17% |
| Sep 30, 2018 | -35.33% |
| Jun 30, 2018 | -35.31% |
| Mar 31, 2018 | -30.43% |